NEO
NEO
US64049M2098
NeoGenomics, Inc.
Loading chart...

Company Profile

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

Latest News

Related stocks

WGS
WGS • United States
GeneDx Holdings Corp.
67.33 USD
2.01B USD 1Y -44.8%
BLLN
BLLN • United States
BillionToOne, Inc.
98.09 USD
4.63B USD
VCYT
VCYT • United States
Veracyte, Inc.
45.23 USD
3.64B USD 1Y +24.2%
SHC
SHC • United States
Sotera Health Company
18.06 USD
5.15B USD 1Y +11.4%
PSNL
PSNL • United States
Personalis, Inc.
16 USD
1.71B USD 1Y +85%
OPK
OPK • United States
Opko Health, Inc.
1.38 USD
1.03B USD 1Y -11.6%
ADPT
ADPT • United States
Adaptive Biotechnologies Corpor
26.49 USD
4.23B USD 1Y +67.8%
CDNA
CDNA • United States
CareDx, Inc.
63.67 USD
3.29B USD 1Y +320.6%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
70.2% p.a.
Max Drawdown (5Y)
-89.7%
Sharpe Ratio (5Y)
-0.28
Beta Factor
1.78
Size Class
Mid Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Unprofitable business model: The company is currently generating net losses.
High market risk: Beta of 1.78 indicates above-average volatility compared to the broader market.
🔴 High valuation risk: Avg P/E of 48.2 (Elevated multiple compression risk)
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (70.2% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -91.9% in the extended horizon.
ende